This paper appears in PLoS, which is an open-access journal. Anyone interested should be able to read it. The study is conducted with hepatitis patients undergoing interferon alpha treatment who previously failed to respond to such treatment; The supplementation potentiates interferon alpha signaling which may act to inhibit viral replication. This may be of interest to some ME/CFS patients with infections. I recently added TMG to my pile of supplements and seem to be experiencing positive results beyond methyl B12 and SAMe supplementation. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. Source Hepatology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. Erratum in PLoS One. 2010;5(11). doi: 10.1371/annotation/14d47e6a-400a-429e-a487-6dd375e04632. Abstract BACKGROUND/AIMS: Treatment of chronic hepatitis C (CHC) with pegylated interferon ? (pegIFN?) and ribavirin results in a sustained response in approximately half of patients. Viral interference with IFN? signal transduction through the Jak-STAT pathway might be an important factor underlying treatment failure. S-adenosyl-L-methionine (SAMe) and betaine potentiate IFN? signaling in cultured cells that express hepatitis C virus (HCV) proteins, and enhance the inhibitory effect of IFN? on HCV replicons. We have performed a clinical study with the aim to evaluate efficacy and safety of the addition of SAMe and betaine to treatment of CHC with pegIFN?/ribavirin. METHODS: In this open-label pilot study, 29 patients with CHC who failed previous therapy with (peg)IFN?/ribavirin were treated with SAMe, betaine, pegIFN?2b and ribavirin. Treatment duration was 6 or 12 months, depending on genotype, and the protocol comprised a stopping rule at week 12 if early virological response (EVR) was not achieved. Virological and biochemical response and safety were assessed throughout the treatment. RESULTS: 29 patients were enrolled and treated according to the study protocol. 79% of the patients were infected with genotype 1, 72% had advanced fibrosis, 76% had previously received pegIFN?/ribavirin, and only 14% achieved EVR to the previous treatment. When treated with the study medications, 17 patients (59%) showed an EVR, only 3 (10%) however achieved a sustained virological response (SVR). SAMe and betaine were found to be safe when used with pegIFN?/ribavirin. CONCLUSION: The addition of SAMe and betaine to pegIFN?/ribavirin improves early virological response in CHC. TRIAL REGISTRATION: ClinicalTrials.gov NCT00310336.